# DATA REPOSITORY FOR TNIK ## ANTI-FIBROTIC PROGRAM ### Figure 2D cell images ### Figure 2 WB raw images ### Figure 2 RNASeq raw data ### Extended Figure 6 #### A549 TNIK KD; hippo pathway Architectural superposition of TNIK inhibitor structures with the predicted INS018_055 binding mode and effects on TGF-β-induced EMT/FMT cellular programs _In vivo_ effects of INS018_055 treatment in mouse models of lung diseases ### Figure 3 data ### Figure 3C pathology ### Figure 4 _In vivo_ effects of INS018_055 treatment by inhalation in rat models of lung fibrosis ### Figure 4 data ### Figure 5 _In-vitro_ and _in vivo_ studies on the effect of INS018_055 on kidney cells or mouse model of kidney fibrosis ### Figure 5A WB raw images ### Figure 5B and 5D UUO pathology images ### Figure 6 Pharmacokinetic analysis in clinical phase I trials ### Extended Data Figure 1 Supplementary figure describing Target ID approach ### Extended Data Figure 2 PandaOmics scores transparency and in-silico validation of TNIK ### Extended Data Figure 3 IPF donor fibroblast and epithelial cell imaging for FMT and EMT assays ### Extended Data Figure 4 SPR assays and cell viability assays ### Extended Data Figure 5 Effect of IN18_055 on TGF-β-induced, or combination of TGF-β and TNF-α induced EMT/FMT cellular programs ### Extended Data Figure 5B ### Extended Data Figure 6 Effect of TNIK deletion on TGF-β signaling in A549 cells ### Extended Data Figure 7 ### Extended Data Figure 8 _In vivo_ study on the effect of combination therapy of INS018_055 and sub-optimal dose Pirfenidone on mouse model of bleomycin induced lung fibrosis ### Extended Data Figure 9 _In vivo_ effects of INS018_055 treatment in combination with maximum therapeutic dose of Pirfenidone in mouse models of lung fibrosis ### Extended Data Figure 10 _in vitro_ and _in vivo_ study of INS018_055 on skin fibrosis ### Figure 3 INS018_055 concentrations in plasma and lung ### Figure 4 INS018_055 concentrations in plasma and lung ### Figure 5 INS018_055 concentrations in plasma and kidney ### Extended Data Figure 8 INS018_055 and pirfenidone concentrations in plasma and lung